OKUR

OnKure Therapeutics, Inc.

NASDAQ: OKUR · HEALTHCARE · BIOTECHNOLOGY

$4.28

-4.04% today

Updated 2026-07-10

Market cap

$184.20M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.32

Dividend yield

—

52W range

$2 – $5

Volume

0.3M

Market cap

$184.20M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.32

Dividend yield

—

52W range

$2 – $5

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-1.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →198 stocks currently score above 75

Price targets

Analyst target

$20.20

+371.96%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -1.25 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-12.94M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-29.51M	$-35.31M	$-52.67M	$-59.52M	$-15.16M
EPS	—	—	—	—	$-4.32
Free cash flow	$-28.09M	$-34.79M	$-51.17M	$-51.87M	$-12.94M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
OKUR	$184.20M	32	4.3	3.0	5.0	6.0	—	Avoid
LLY	$1.08T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$623.71B	57	4.7	9.0	2.7	6.0	-88.25%	Buy
ABBV	$441.54B	63	4.0	8.0	4.7	5.0	-69.18%	Buy
UNH	$392.03B	54	5.3	5.5	4.0	5.5	-32.08%	Buy
MRK	$308.90B	50	3.3	8.0	2.7	5.0	-52.59%	Hold

Smart narrative

OnKure Therapeutics, Inc. trades at $4.28. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -1.25, it sits in the distress.

Frequently asked questions

What is OnKure Therapeutics, Inc.'s stock price?

OnKure Therapeutics, Inc. (OKUR) trades at $4.28.

Is OnKure Therapeutics, Inc. overvalued?

OnKure Therapeutics, Inc. carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of OnKure Therapeutics, Inc. (OKUR)?

The 12-month analyst consensus target is $20.20, about 372.0% above the current $4.28. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

OnKure Therapeutics, Inc.'s Altman Z-Score is -1.25, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

onkuretherapeutics.com

Quick metrics

P/S ratio—

ROE-31.87%

Beta—

50D MA$4.27

200D MA$3.38

Shares out0.04B

Float0.02B

Short ratio—

Avg volume0.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

OKUR vs LLY →OKUR vs JNJ →OKUR vs ABBV →Stock screener →